文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

华盛顿特区和约翰·霍普金斯大学艾滋病毒队列中整合酶抑制剂的处方差异

Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.

作者信息

Monroe Anne K, Levy Matthew E, Greenberg Alan E, Keruly Jeanne C, Moore Richard D, Horberg Michael A, Kulie Paige, Mohanraj Bernadine S, Kumar Princy N, Castel Amanda D

机构信息

The George Washington University, Washington, DC, USA.

Westat, Rockville, Maryland, USA.

出版信息

Open Forum Infect Dis. 2021 Jul 27;8(8):ofab338. doi: 10.1093/ofid/ofab338. eCollection 2021 Aug.


DOI:10.1093/ofid/ofab338
PMID:34631925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8496514/
Abstract

Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy for people with HIV. Because there can be disparities in prescribing and uptake of novel and/or recommended therapies, this analysis assessed potential INSTI prescribing disparities using a combined data set from the Johns Hopkins HIV Clinical Cohort and the DC Cohort. We performed multivariable logistic regression to identify factors associated with ever being prescribed an INSTI. Disparities were noted, including clinic location, age, and being transgender. Identifying disparities may allow clinicians to focus their attention on these individuals and ensure that therapy decisions are grounded in valid clinical reasons.

摘要

整合酶抑制剂(INSTIs)被专家小组推荐作为HIV感染者的初始治疗方案。由于新型和/或推荐疗法在处方和使用方面可能存在差异,本分析使用约翰·霍普金斯HIV临床队列和华盛顿特区队列的合并数据集评估了潜在的整合酶抑制剂处方差异。我们进行了多变量逻辑回归,以确定与曾接受整合酶抑制剂处方相关的因素。发现了一些差异,包括诊所位置、年龄和跨性别身份。识别这些差异可能使临床医生将注意力集中在这些个体身上,并确保治疗决策基于有效的临床理由。

相似文献

[1]
Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.

Open Forum Infect Dis. 2021-7-27

[2]
Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).

Infection. 2021-12

[3]
Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.

AIDS. 2019-7-15

[4]
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.

HIV Med. 2018-11-21

[5]
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.

Virus Genes. 2019-6

[6]
Primary resistance to integrase strand-transfer inhibitors in Europe.

J Antimicrob Chemother. 2015-10

[7]
Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis.

Open Forum Infect Dis. 2019-2-12

[8]
Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.

AIDS Res Hum Retroviruses. 2018-7

[9]
Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.

Curr HIV Res. 2019

[10]
Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection.

Pediatr Infect Dis J. 2020-5

引用本文的文献

[1]
Prevention, treatment and cure of HIV infection.

Nat Rev Microbiol. 2023-10

[2]
Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.

JAMA. 2023-1-3

本文引用的文献

[1]
HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: A retrospective study.

PLoS Med. 2020-5-28

[2]
HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals.

Drugs. 2020-7

[3]
Changes in HIV antiretroviral prescribing practices in the United States.

Int J STD AIDS. 2020-1

[4]
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.

Infect Dis Ther. 2020-3

[5]
2019 update of the drug resistance mutations in HIV-1.

Top Antivir Med. 2019-9

[6]
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.

Medicine (Baltimore). 2019-8

[7]
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.

N Engl J Med. 2019-7-22

[8]
Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.

AIDS. 2019-6-1

[9]
Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.

Medicine (Baltimore). 2018-10

[10]
Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system.

HIV Clin Trials. 2018-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索